久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

上海非利加實業有限公司Logo

熱門詞: 進口電動溫度調節閥結構圖|進口電動溫度調節閥數據表進口電動高溫調節閥-德國進口電動高溫法蘭調節閥進口電動蒸汽調節閥-德國進口電動蒸汽調節閥

當前位置: 首頁 > 所有品牌 > Arena
Arena
Arena Arena

Arena Pharmaceuticals  
Arena制藥公司是一家生物制藥公司發現,開發和商品化的藥物,在治療領域的心血管疾病,中樞神經系統,炎癥和代謝性疾病的重點。該公司正在開發一種化合物,這種行為稱為G蛋白偶聯受體的藥物靶標,使用其專利技術,其中包括組成物激活受體技術和黑色素的管道。競技場的產品包括APD811,第二階段的臨床試驗5-HT2C5 - 羥色胺受體激動劑,其將被用于治療肥胖和APD334,I期臨床試驗的產品,用于治療失眠,使用。其研究和發展計劃還包括APD597,APD916,APD791和APD125,所有這一切都是口頭的候選藥物。該公司始建于1997年4月由Dominic P.貝安和杰克·利夫和總部設在加利福尼亞州圣迭戈。

Our Focus
We are a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, or GPCRs, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.
Our Research & Development Pipeline
Lorcaserin is our most advanced investigational drug candidate and is intended for weight management, including weight loss and maintenance of weight loss. In October 2010, the US Food and Drug Administration, or FDA, issued a Complete Response Letter, or CRL, with respect to the lorcaserin New Drug Application, or NDA, we submitted in December 2009. In the CRL, the FDA stated that it completed its review of the NDA and determined that it could not approve the application in its then present form.
After completing various studies, analyses and other activities in response to the lorcaserin CRL, in December 2011, we resubmitted the lorcaserin NDA. The FDA accepted the resubmission for filing and review and assigned a new Prescription Drug User Fee Act, or PDUFA, target date of June 27, 2012.
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee met on May 10, 2012, to discuss the lorcaserin NDA. The advisory committee voted 18 to 4, with one abstention, that the available data demonstrate that the potential benefits of lorcaserin outweigh the potential risks when used long-term in a population of overweight and obese individuals.
We are also seeking regulatory approval for lorcaserin in the European Union. On March 2, 2012, we filed a marketing authorization application, or MAA, for lorcaserin through the centralized procedure with the European Medicines Agency, or EMA, and the EMA subsequently accepted the filing. The acceptance of the MAA filing begins the EMA’s review process.
In addition to lorcaserin, our prioritized earlier-stage programs include APD811, an internally discovered, orally available agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension; APD334, an internally discovered, orally available agonist of the S1P1 receptor intended for the treatment of a number of conditions related to autoimmune diseases, including multiple sclerosis; APD371, an internally discovered, orally available agonist of the cannabinoid receptor 2 intended for the treatment of pain; and GPR119 agonists, intended for the treatment of type 2 diabetes. Our internally discovered, oral drug candidates also include temanogrel, which was formerly called APD791 and is intended for the treatment of arterial thrombosis and other related conditions, and nelotanserin, which we previously studied for insomnia and was formerly called APD125.
Our Strategy
The key elements of our general strategy are as follows:
Focus on lorcaserin. We intend to focus our efforts on seeking approval for lorcaserin in the United States, the European Union and other select markets outside of the United States. Pending regulatory approvals, we intend to commercialize lorcaserin in the United States under our marketing and supply agreement with Eisai and in other markets with one or more collaborators or independently.
Selectively advance our other lead candidates. We intend to selectively advance our pipeline of drug candidates independently or through licensing, collaborations or other opportunities.
Maintain research and development capabilities to advance our pipeline. Our technologies, our drug discovery infrastructure and the integrated approach to research used by our scientists have allowed us to identify and develop a number of GPCR targets and novel compounds, and our development infrastructure has allowed us to develop compounds through NDA filing. We expect that our research and development capabilities will continue to play an important role in the support of the further development and potential commercialization of lorcaserin. We intend to maintain our research and development capabilities to selectively advance our programs and to discover additional drug candidates.

關于我們客戶服務產品分類法律聲明
主站蜘蛛池模板: 国产第二十页 | 亚洲欧美综合图区官网 | 日韩专区第一页 | 日韩欧美国产另类 | 成a人片亚洲日本久久 | 国产在线视频不卡 | 久久久久久久国产精品 | 亚洲黄色一区 | 亚洲欧美视频在线观看 | 久久精品国产免费中文 | 精品一区二区三区四区电影 | 美女牲交视频一级毛片 | 欧美在线视频二区 | 欧美成人高清视频 | 国产最新网站 | 久久久噜噜噜www成人网 | 国内久久 | 不卡日本| 欧美国产中文 | 久久久久女人精品毛片九一 | 欧美亚洲综合一区 | 亚洲精品美女久久777777 | 日韩精品一区在线 | 伊人久久精品久久亚洲一区 | 成人精品久久 | 国产视频一区二区在线播放 | 国模私拍一区二区 | 国产自在线拍 | 热久久国产欧美一区二区精品 | 亚洲国产精品嫩草影院久久 | 久久er99热精品一区二区 | 免费观看a毛片一区二区不卡 | 国产啪在线91 | 美国一级大黄大色毛片视频一 | 国产在线午夜 | 国产精品成人久久久 | 国产v欧美v日韩在线观看 | 欧美在线观看一区二区三区 | 91久久国产综合精品女同国语 | 久久一区二区精品综合 | 国产成人青青热久免费精品 |